PE20171305A1 - Formulaciones inyectables de paracetamol - Google Patents
Formulaciones inyectables de paracetamolInfo
- Publication number
- PE20171305A1 PE20171305A1 PE2017001066A PE2017001066A PE20171305A1 PE 20171305 A1 PE20171305 A1 PE 20171305A1 PE 2017001066 A PE2017001066 A PE 2017001066A PE 2017001066 A PE2017001066 A PE 2017001066A PE 20171305 A1 PE20171305 A1 PE 20171305A1
- Authority
- PE
- Peru
- Prior art keywords
- paracetamol
- formulation
- alcohol
- injectable formulations
- flebitis
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005489 paracetamol Drugs 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 235000019441 ethanol Nutrition 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION INYECTABLE DE PARACETAMOL QUE COMPRENDE: A) 250 mg/ml DE PARACETAMOL O SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y B) UN SISTEMA DE SOLVENTES QUE COMPRENDE i) 0-40% P/V DE GLICOFUROL, ii) 0-30% P/V DE UN ALCOHOL DE CADENA CORTA TAL COMO ALCOHOL ETILICO, ALCOHOL ISOPROPILICO O MEZCLAS DE LOS MISMOS, iii) 0-5% P/V DE UN ESTABILIZADOR, iv) 0-55% P/V DE OTRO SOLVENTE TAL COMO AGENTES TENSOACTIVOS, CICLODEXTRINAS, N-METIL-PIRROLIDONA, ENTRE OTROS, Y v) AGUA PARA COMPLETAR EL VOLUMEN DE LA FORMULACION. ADICIONALMENTE DICHA FORMULACION COMPRENDE INGREDIENTES AUXILIARES TAL COMO ANTIOXIDANTES, MODIFICADORES DE pH, ENTRE OTROS, Y SON APTAS PARA SU ADMINISTRACION POR VIA INTRAVENOSA LENTA CON EFECTOS SECUNDARIOS MINIMIZADOS TALES COMO FLEBITIS Y DOLOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4102MU2014 | 2014-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171305A1 true PE20171305A1 (es) | 2017-09-05 |
Family
ID=55022620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001066A PE20171305A1 (es) | 2014-12-20 | 2015-11-17 | Formulaciones inyectables de paracetamol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20180000940A1 (es) |
| EP (1) | EP3233055B1 (es) |
| JP (1) | JP2017538762A (es) |
| KR (1) | KR20170099911A (es) |
| CN (1) | CN107205924A (es) |
| AR (1) | AR103188A1 (es) |
| AU (1) | AU2015365533A1 (es) |
| BR (1) | BR112017012975B1 (es) |
| CA (1) | CA2969303A1 (es) |
| CL (1) | CL2017001629A1 (es) |
| CO (1) | CO2017006268A2 (es) |
| CU (1) | CU20170088A7 (es) |
| DO (1) | DOP2017000134A (es) |
| EA (1) | EA201791409A1 (es) |
| EC (1) | ECSP17038668A (es) |
| ES (1) | ES3009433T3 (es) |
| IL (1) | IL252729A0 (es) |
| JO (1) | JO3689B1 (es) |
| MA (1) | MA40599A1 (es) |
| MD (1) | MD20170071A2 (es) |
| MX (1) | MX383557B (es) |
| MY (1) | MY203965A (es) |
| PE (1) | PE20171305A1 (es) |
| PH (1) | PH12017501005B1 (es) |
| PL (1) | PL3233055T3 (es) |
| SG (1) | SG11201704435PA (es) |
| TN (1) | TN2017000232A1 (es) |
| TW (1) | TWI649097B (es) |
| UA (1) | UA122136C2 (es) |
| UY (1) | UY36466A (es) |
| WO (1) | WO2016097899A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107229455B (zh) | 2016-03-24 | 2019-09-17 | 阿里巴巴集团控股有限公司 | 一种业务处理方法、装置及系统 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (fr) * | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| IT1301976B1 (it) * | 1998-07-31 | 2000-07-20 | Angelini Ricerche Spa | Composizione farmaceutica iniettabile a base di paracetamolo |
| IT1313579B1 (it) | 1999-07-30 | 2002-09-09 | Acraf | Composizione farmaceutica liquida a base di paracetamolo. |
| ITMI20012135A1 (it) | 2001-10-16 | 2003-04-16 | Bioren S A | Soluzioni iniettabili pronte all'uso di paracetamolo |
| CA2609242A1 (en) * | 2005-05-27 | 2006-11-30 | Panacea Biotec Ltd. | Injectable compositions and process for preparation of such compositions |
| EP1973527B1 (en) * | 2005-12-15 | 2009-10-07 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for parenteral administration |
| EP2170313A2 (en) | 2007-06-18 | 2010-04-07 | Combino Pharm, S.L. | Aqueous formulations of acetaminophen for injection |
| WO2009098716A2 (en) | 2008-01-17 | 2009-08-13 | Aptuit Laurus Private Limited | Stable pharmaceutical aqueous compositions |
| UA103906C2 (ru) * | 2008-10-09 | 2013-12-10 | Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А. | Жидкая фармацевтическая композиция, которая содержит парацетамол |
| KR101587942B1 (ko) * | 2010-06-30 | 2016-01-22 | 트로이카 파마슈티칼스 리미티드 | 파라세타몰을 포함한 약학 조성물 및 이것의 제조방법 |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| CN102258485A (zh) * | 2011-01-11 | 2011-11-30 | 北京润德康医药技术有限公司 | 一种含对乙酰氨基酚的注射用制剂及其应用 |
| CN102600068A (zh) * | 2011-01-24 | 2012-07-25 | 联康药业克雷恩特塞提斯制药实验室有限责任公司 | 稳定即用的可注射扑热息痛制剂 |
-
2015
- 2015-11-17 MY MYPI2017701979A patent/MY203965A/en unknown
- 2015-11-17 AU AU2015365533A patent/AU2015365533A1/en not_active Abandoned
- 2015-11-17 CN CN201580069391.5A patent/CN107205924A/zh active Pending
- 2015-11-17 PE PE2017001066A patent/PE20171305A1/es unknown
- 2015-11-17 EA EA201791409A patent/EA201791409A1/ru unknown
- 2015-11-17 SG SG11201704435PA patent/SG11201704435PA/en unknown
- 2015-11-17 CU CUP2017000088A patent/CU20170088A7/es unknown
- 2015-11-17 CA CA2969303A patent/CA2969303A1/en not_active Abandoned
- 2015-11-17 US US15/537,642 patent/US20180000940A1/en not_active Abandoned
- 2015-11-17 EP EP15816228.9A patent/EP3233055B1/en active Active
- 2015-11-17 JP JP2017533277A patent/JP2017538762A/ja active Pending
- 2015-11-17 PH PH1/2017/501005A patent/PH12017501005B1/en unknown
- 2015-11-17 MD MDA20170071A patent/MD20170071A2/ro not_active Application Discontinuation
- 2015-11-17 MX MX2017008264A patent/MX383557B/es unknown
- 2015-11-17 UA UAA201706668A patent/UA122136C2/uk unknown
- 2015-11-17 MA MA40599A patent/MA40599A1/fr unknown
- 2015-11-17 KR KR1020177017759A patent/KR20170099911A/ko not_active Ceased
- 2015-11-17 TN TN2017000232A patent/TN2017000232A1/en unknown
- 2015-11-17 WO PCT/IB2015/058876 patent/WO2016097899A1/en active Application Filing
- 2015-11-17 PL PL15816228.9T patent/PL3233055T3/pl unknown
- 2015-11-17 BR BR112017012975-2A patent/BR112017012975B1/pt active IP Right Grant
- 2015-11-17 ES ES15816228T patent/ES3009433T3/es active Active
- 2015-11-27 TW TW104139783A patent/TWI649097B/zh not_active IP Right Cessation
- 2015-12-09 JO JOP/2015/0303A patent/JO3689B1/ar active
- 2015-12-21 UY UY0001036466A patent/UY36466A/es unknown
- 2015-12-21 AR ARP150104211A patent/AR103188A1/es unknown
-
2017
- 2017-06-06 IL IL252729A patent/IL252729A0/en unknown
- 2017-06-09 DO DO2017000134A patent/DOP2017000134A/es unknown
- 2017-06-20 CL CL2017001629A patent/CL2017001629A1/es unknown
- 2017-06-20 EC ECIEPI201738668A patent/ECSP17038668A/es unknown
- 2017-06-23 CO CONC2017/0006268A patent/CO2017006268A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005774A2 (es) | Lípidos con amina ionizables | |
| CY1124075T1 (el) | Παρασιτοκτονες στοματικες κτηνιατρικες συνθεσεις οι οποιες περιλαμβανουν δραστικους παραγοντες συστημικης δρασης, μεθοδοι και χρησεις αυτων | |
| CY1121402T1 (el) | Παρασιτοκτονες συνθεσεις οι οποιες περιλαμβανουν εναν δραστικο παραγοντα ισοξαζολινης, μεθοδοι και χρησεις αυτων | |
| CL2020002055A1 (es) | Macrociclos como moduladores del regulador de conductncia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos. | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| PE20170911A1 (es) | Capsulas blandas de calcifediol | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| BR112016006171A2 (pt) | formulações de espuma e dispositivo para sua entrega | |
| AR096338A1 (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles | |
| CO2018012502A2 (es) | Formulaciones y métodos para el tratamiento de organismos fotosintéticos y la mejora de las calidades y cantidades de rendimientos con formulaciones de compuestos de glicano | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX370928B (es) | El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal. | |
| PE20150928A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| PE20171305A1 (es) | Formulaciones inyectables de paracetamol | |
| PE20190707A1 (es) | Formulaciones de buprenorfina de liberacion sostenida |